Pulnovo Medical Raises $100M Led by Medtronic to Scale PADN Therapy for Pulmonary Hypertension and Heart Failure

Pulnovo Medical just rang the bell with a $100M strategic round, and when Medtronic leads, the room doesn’t clap politely… it recalibrates. Founded in 2013 and now operating across New York and key Asia-Pacific hubs, Pulnovo Medical has been building something most people didn’t fully appreciate until now. Not another incremental device. Not another “me too” therapy. They’ve been quietly wiring a new lane into cardiopulmonary care through pulmonary artery denervation, or PADN. It’s precise, interventional, and aimed straight at pulmonary hypertension and heart failure, 2 of the toughest rooms in medicine where outcomes don’t come easy and excuses don’t last long.

Big respect to Jessie Lian Jia stepping in as CEO and driving this next chapter, alongside Cynthia Chen, who continues to anchor the company as Chairlady and President. And with Francis Duhay shaping the clinical strategy, you’ve got leadership that understands both the science and the stakes. That combination tends to age well when the pressure turns up.

This round brought familiar heavyweights back to the table. EQT, Qiming Venture Partners, Gaorong Capital, OrbiMed, and Lilly Asia Ventures didn’t just show up for the optics. They leaned in again. That tells you the data, the discipline, and the direction are lining up. When capital repeats, it’s rarely out of nostalgia.

More than 1,000 clinical applications globally, FDA Breakthrough Device designation, CE-MDR certification, NMPA approval. Those aren’t vanity metrics. That’s a company stacking receipts across regulatory systems that don’t hand out gold stars for effort. Pulnovo Medical didn’t just build a device. They built credibility in markets that demand proof, not promises.

The play here is deeper than a single product. PADN isn’t just a procedure, it’s a shift in how we think about treating pulmonary pressure at its neurological roots. If you’re a hospital system, a cardiologist, or a partner in the cardiovascular ecosystem, this isn’t noise. This is signal with teeth.

And the Medtronic piece? That’s not just capital. That’s distribution gravity, operational muscle, and a global commercialization engine waiting to be switched on at the right moment. Pulnovo Medical isn’t trying to be loud. They’re being precise. And in this game, precision tends to win when the room finally realizes what it’s looking at.